Condition: Biliary Tract Cancer · Melanoma · Sponsor: Hangzhou Hanx Biopharmaceuticals, Ltd.
Phase IIa study of HX009+ IN10018 in combination with or without standard chemotherapy in patients with advanced solid tumours including biliary tract malignancies and malignant melanoma
This description comes directly from the study's public registry record.
Shuai Wang · +86027-65524978-8001 · kevin.wang@hanxbio.com
Always discuss trial participation with your own doctor first.
| Peking University Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06708663